Antioxidant Therapies in the Treatment of Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39456199/
Several studies have proposed a potential role for oxidative stress in the development of multiple sclerosis (MS). For this reason, it seems tentative to think that treatment with antioxidant substances...
This review highlights the potential role of antioxidants in multiple sclerosis (MS) treatment, summarizing experimental model findings and clinical trials, while emphasizing the need for long-term, large-scale studies to confirm efficacy.
Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39177889/
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite the availability of numerous disease-modifying...
This review explores current and emerging therapies for multiple sclerosis, focusing on novel targets like monoclonal antibodies, CAR T cell therapy, microglia, ferroptosis, and microbiota-based interventions for holistic management.
Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38529035/
https://inplasy.com/?s=202320071, identifier: 202320071.
This systematic review evaluates the efficacy and safety of disease-modifying therapies for progressive multiple sclerosis, finding mitoxantrone, siponimod, and ocrelizumab most effective in delaying progression and mitigating disability.
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39379875/
Limitations of these analyses included the potential for confounding due to pseudoatrophy, and a lack of long-term clinical data for BVL. Our findings suggest that important differences in BVL may...
This study reviewed randomized trials on disease-modifying therapies (DMTs) in relapsing multiple sclerosis (RMS), highlighting significant differences in brain volume loss (BVL) reduction, emphasizing the need for further BVL-focused research.
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39749348/
The immunogenicity profile of biosim-NTZ was confirmed to match that of ref-NTZ in healthy subjects and patients with RRMS by applying highly sensitive methods.
Biosimilar natalizumab demonstrated matching immunogenicity to reference natalizumab in RRMS patients and healthy subjects, with similar ADA/NAb incidence and titers, confirming biosimilarity using highly sensitive bioanalytical assays.